AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- Drug: Treatment A - AZD1775 administered under fasted conditionsDrug: Treatment B - AZD1775 administered under fed conditions.
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT03315091
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.
Phase 1
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT03313336
- Locations
- 🇩🇪
Research Site, Berlin, Germany
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: Wee-1 kinase inhibitor AZD1775
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT03313557
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
Phase 1
Terminated
- Conditions
- Plaque Psoriasis Vulgaris
- Interventions
- Drug: PlaceboDrug: AZD0284 oral solution 2.5 mg/mL
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT03310320
- Locations
- 🇩🇰
Research Site, Odense, Denmark
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
Phase 3
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS)Drug: Placebo
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 196
- Registration Number
- NCT03303521
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1324
- Registration Number
- NCT03298451
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Assessment of Asthma Control Level in Malaysia
Completed
- Conditions
- Asthma Control Level
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 398
- Registration Number
- NCT03295331
- Locations
- 🇲🇾
Hospital Serdang, Kajang, Selangor, Malaysia
🇲🇾Institut Perubatan Respiratori, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Other COPD medication
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26839
- Registration Number
- NCT03290287
- Locations
- 🇬🇧
Clinical Practice Research Datalink, London, United Kingdom
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
Phase 3
Completed
- Conditions
- Somatic BRCA1/2 MutationsHER2-ve Metastatic Breast CancerGermline BRCA1/2 Mutations
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT03286842
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
Phase 1
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS)
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT03283267
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
© Copyright 2025. All Rights Reserved by MedPath